Background: Renal transplantation is recognised as being the optimal treatment modality for many patients with end stage renal disease. This analysis aimed to explore the equity of access to renal transplantation in the UK. Methods: Transplant activity and waiting list data were obtained from NHS Blood and Transplant, demographic and laboratory data were obtained from the UK Renal Registry. All incident RRT patients starting treatment between 1st January 2004 and 31st December 2006 from 65 renal centres were considered for inclusion. The cohort was followed until 31st December 2008 (or until transplantation or death, whichever was earliest). Results: Age, ethnicity and primary renal diagnosis were associated with both accessing the kidney transplant waiting list and receiving an organ. A patient starting dialysis in a non-transplanting renal centre was less likely to be registered for transplantation (OR 0.90, 95% CI 0.82–0.99) or receive a transplant from a donor after cardiac death or a living kidney donor (OR 0.69, 95% CI 0.60–0.79) compared with patients cared for in transplanting renal centres. Once registered for kidney transplantation, patients in both transplanting and nontransplanting renal centres had an equal chance of receiving a transplant from a donor after brain stem death (OR 0.92, 95% CI 0.78–1.08). Conclusion: There is wide variation in access to kidney transplantation between UK renal centres which cannot be explained by differences in case mix.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.